Antihypertensive properties of cryptenamine used with reserpine and methyclothiazide.
D000328:Adult; D000368:Aged; D000856:Anorexia Nervosa / Q000139:chemically induced; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002712:Chlorides / Q000097:blood; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008736:Methyclothiazide / Q000009:adverse effects / Q000494:pharmacology*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011188:Potassium / Q000097:blood; D011674:Pulse / Q000187:drug effects; D012110:Reserpine / Q000009:adverse effects / Q000494:pharmacology*; D012964:Sodium / Q000097:blood; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood; D014703:Veratrum / Q000009:adverse effects / Q000494:pharmacology*
D000959:Antihypertensive Agents; D001786:Blood Glucose; D002712:Chlorides; D002245:Carbon Dioxide; D014527:Uric Acid; D012110:Reserpine; D014508:Urea; D012964:Sodium; D008736:Methyclothiazide; D011188:Potassium